Leadership & Pay ·
Spruce Biosciences reported a net loss of $16.2 million, or $(6.68) per share, for the second quarter ended June 30…
SPRBSpruce Biosciences, Inc.
Spruce Biosciences reported a net loss of $16.2 million, or $(6.68) per share, for the second quarter ended June 30, 2026, with cash and cash equivalents rising to $96.3 million from $48.9 million at year-end 2025. The company announced a combined $5.5 million strategic investment from Cure Sanfilippo Foundation and the National MPS Society to fund an Expanded Access Program for its lead candidate TA-ERT. Management anticipates submitting a Biologics License Application (BLA) for TA-ERT in the fourth quarter of 2026, with the TrAnsform confirmatory study also expected to initiate then. Additionally, Spruce appointed Adrian Quartel as Chief Medical Officer and Jessica Cohen Pfeffer as Vice President of Clinical Development to support regulatory and commercial readiness. The company operates in the biopharmaceutical industry, developing novel therapies for neurological disorders.